Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
US Stock Market Movers: StablecoinX recorded significant declines on October 22, driven by shareholder supply pressure and ENA unlocking.

US Stock Market Movers: StablecoinX recorded significant declines on October 22, driven by shareholder supply pressure and ENA unlocking.

Bitget异动解读Bitget异动解读2026/10/22 14:15
Show original

StablecoinX October 22 Sharp Drop Analysis

Keywords: Share supply pressure, ENA unlocking

1. On September 17, the company’s updated prospectus involved the issuance of approximately 19.12 million shares and a shareholder resale of about 12.67 million shares. The new share issuance and potential resale may bring supply pressure.

2. Starting from October 5, the 48-month lock-up period for ENA held by Ethena-related parties is permanently terminated; although there are still token sale control measures, future disposal arrangements remain uncertain.

(Disclaimer: This content is generated by AI technology summarizing publicly available information and is for reference only. It does not constitute investment advice.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%

Researchers combined Amgen's Imdelltra with AstraZeneca's Imfinzi and found that for patients with aggressive lung cancer whose tumors had already spread, this combination extended survival by about eight months compared to Imfinzi monotherapy. Small cell lung cancer is one of the cancer types with the worst prognosis.

智通财经•2026/10/25 02:56
Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%